{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:00:23Z","timestamp":1794618023522,"version":"4.9.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["20720250004"],"award-info":[{"award-number":["20720250004"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82202500"],"award-info":[{"award-number":["82202500"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32400779"],"award-info":[{"award-number":["32400779"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017357","name":"Science and Technology Projects of Fujian Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.xcrm.2026.102688","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T15:04:22Z","timestamp":1773846262000},"page":"102688","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["A bispecific nanobody-drug conjugate targeting TROP2 and c-Met for low-concentration, single-dose treatment of pancreatic cancer"],"prefix":"10.1016","volume":"7","author":[{"given":"Wenjing","family":"Ning","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongye","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fentian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanzhi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningshao","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.102688_bib1","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.xcrm.2026.102688_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.50756","article-title":"NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis","volume":"7","author":"Nichetti","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.xcrm.2026.102688_bib3","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102688_bib4","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102688_bib5","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2026.102688_bib6","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1158\/1078-0432.CCR-18-1955","article-title":"Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression","volume":"25","author":"Bernard","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102688_bib7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102688_bib8","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1126\/science.1171362","article-title":"Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer","volume":"324","author":"Olive","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.102688_bib9","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(24)00511-4","article-title":"Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis","volume":"25","author":"Mastrantoni","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2026.102688_bib10","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102688_bib11","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/1078-0432.CCR-23-1725","article-title":"Spatiotemporal Quantification of HER2-targeting Antibody-Drug Conjugate Bystander Activity and Enhancement of Solid Tumor Penetration","volume":"30","author":"Wei","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102688_bib12","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","article-title":"Antibody-drug conjugates: Recent advances in linker chemistry","volume":"11","author":"Su","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.xcrm.2026.102688_bib13","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","article-title":"BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study","volume":"25","author":"Ma","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2026.102688_bib14","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.2024.42.16_suppl.3002","article-title":"Phase I\/II first-in-human study to evaluate the safety and efficacy of tissue factor-ADC MRG004A in patients with solid tumors","volume":"42","author":"Park","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102688_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.10.158","article-title":"132MO Anti-claudin18.2 (CLDN18.2) antibody-drug conjugate (ADC) IBI343 in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC): Updated results from a phase I study","volume":"35","author":"Yu","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2026.102688_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1332489","article-title":"Targeting Trop2 in solid tumors: a look into structures and novel epitopes","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.102688_bib17","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12943-024-02184-8","article-title":"Chimeric antigen receptor macrophages targeting c-MET(CAR-M-c-MET) inhibit pancreatic cancer progression and improve cytotoxic chemotherapeutic efficacy","volume":"23","author":"Zheng","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.xcrm.2026.102688_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eururo.2021.10.025","article-title":"Targeting c-Met to Improve Immune Checkpoint Inhibition in Metastatic Renal Cell Carcinoma","volume":"81","author":"Lindner","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.xcrm.2026.102688_bib19","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.21037\/atm-22-5976","article-title":"A literature review of the promising future of TROP2: a potential drug therapy target","volume":"10","author":"Wen","year":"2022","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.102688_bib20","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.7150\/thno.98178","article-title":"Trop2-targeted therapies in solid tumors: advances and future directions","volume":"14","author":"Liu","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.xcrm.2026.102688_bib21","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1038\/s41467-021-24367-3","article-title":"Structural basis of the activation of c-MET receptor","volume":"12","author":"Uchikawa","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102688_bib22","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/med.21885","article-title":"Recent progress in the imaging of c-Met aberrant cancers with positron emission tomography","volume":"42","author":"Floresta","year":"2022","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.xcrm.2026.102688_bib23","doi-asserted-by":"crossref","first-page":"833","DOI":"10.5483\/BMBRep.2008.41.12.833","article-title":"The hepatocyte growth factor\/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis","volume":"41","author":"You","year":"2008","journal-title":"BMB Rep."},{"key":"10.1016\/j.xcrm.2026.102688_bib24","doi-asserted-by":"crossref","first-page":"D494","DOI":"10.1093\/nar\/gkad783","article-title":"MultifacetedProtDB: a database of human proteins with multiple functions","volume":"52","author":"Bertolini","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.102688_bib25","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/s41401-024-01279-8","article-title":"A novel bispecific antibody drug conjugate targeting HER2 and HER3 with potent therapeutic efficacy against breast cancer","volume":"45","author":"Zong","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.xcrm.2026.102688_bib26","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1039\/D0CS00310G","article-title":"Site-selective modification strategies in antibody-drug conjugates","volume":"50","author":"Walsh","year":"2021","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.xcrm.2026.102688_bib27","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102688_bib28","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102688_bib29","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1158\/1535-7163.MCT-21-0580","article-title":"Cellular-Resolution Imaging of Bystander Payload Tissue Penetration from Antibody-Drug Conjugates","volume":"21","author":"Khera","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.xcrm.2026.102688_bib30","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/cac2.12616","article-title":"Engineering heavy chain antibody-drug conjugates against solid tumors for a one-shot kill","volume":"44","author":"Liu","year":"2024","journal-title":"Cancer Commun."},{"key":"10.1016\/j.xcrm.2026.102688_bib31","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1158\/0008-5472.CAN-15-1795","article-title":"Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models","volume":"76","author":"Li","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102688_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117550","article-title":"Modulating autophagy to boost the antitumor efficacy of TROP2-directed antibody-drug conjugate in pancreatic cancer","volume":"180","author":"Xu","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.xcrm.2026.102688_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0362-8","article-title":"Apoptotic cell-derived exosomes: messages from dying cells","volume":"52","author":"Kakarla","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.xcrm.2026.102688_bib34","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s40265-020-01337-5","article-title":"Sacituzumab Govitecan: First Approval","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.xcrm.2026.102688_bib35","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2443538","article-title":"Antibodies to watch in 2025","volume":"17","author":"Crescioli","year":"2025","journal-title":"mAbs"},{"key":"10.1016\/j.xcrm.2026.102688_bib36","doi-asserted-by":"crossref","first-page":"6135","DOI":"10.1021\/acs.analchem.0c05376","article-title":"Characterization of Antibody-Drug Conjugate Pharmacokinetics and in Vivo Biotransformation Using Quantitative Intact LC-HRMS and Surrogate Analyte LC-MRM","volume":"93","author":"Huang","year":"2021","journal-title":"Anal. Chem."},{"key":"10.1016\/j.xcrm.2026.102688_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/antib8010011","article-title":"Multiplex LC-MS\/MS Assays for Clinical Bioanalysis of MEDI4276, an Antibody-Drug Conjugate of Tubulysin Analogue Attached via Cleavable Linker to a Biparatopic Humanized Antibody against HER-2","volume":"8","author":"Faria","year":"2019","journal-title":"Antibodies"},{"key":"10.1016\/j.xcrm.2026.102688_bib38","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","article-title":"Bispecific antibody drug conjugates: Making 1+1>2","volume":"14","author":"Gu","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.xcrm.2026.102688_bib39","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-10-2939","article-title":"Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys","volume":"17","author":"Cardillo","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102688_bib40","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1158\/1078-0432.CCR-16-1568","article-title":"ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence","volume":"23","author":"Wang","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102688_bib41","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1021\/acs.chemrev.0c00383","article-title":"Challenges and Opportunities in Cancer Drug Resistance","volume":"121","author":"Ward","year":"2021","journal-title":"Chem. Rev."},{"key":"10.1016\/j.xcrm.2026.102688_bib42","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood.2024024442","article-title":"Antibody-drug conjugate adverse effects can be understood and addressed based on immune complex clearance mechanisms","volume":"144","author":"Taylor","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102688_bib43","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the safety of antibody\u2013drug conjugates for patients with solid tumours","volume":"20","author":"Tarantino","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102688_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115193","article-title":"Clinical pharmacology strategies to accelerate the development of polatuzumab vedotin and summary of key findings","volume":"207","author":"Liao","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.xcrm.2026.102688_bib45","first-page":"165","article-title":"Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies","volume":"72","author":"Tarantino","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.xcrm.2026.102688_bib46","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2026.102688_bib47","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adk1894","article-title":"Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data","volume":"10","author":"Rubahamya","year":"2024","journal-title":"Sci. Adv."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126001059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126001059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T08:21:21Z","timestamp":1778919681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126001059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2666379126001059"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102688","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A bispecific nanobody-drug conjugate targeting TROP2 and c-Met for low-concentration, single-dose treatment of pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102688","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102688"}}